<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01546181</url>
  </required_header>
  <id_info>
    <org_study_id>C10-03</org_study_id>
    <secondary_id>2010-A00492-37</secondary_id>
    <nct_id>NCT01546181</nct_id>
  </id_info>
  <brief_title>Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases</brief_title>
  <acronym>iPhot</acronym>
  <official_title>Observational, Follow-up Study of Adaptive Optics Retinal Imaging in Controls and During Retinal or General Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using an adaptive optics imaging device, retinal structures are observed in healthy and
      diseased subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most cases of severe visual loss in developed countries are due to retinal diseases affecting
      a specialized class of neurons, the photoreceptors. Currently available systems for retinal
      imaging in humans do not allow neuronal imaging at the cellular level, which is crucial to
      understand, diagnose and monitor retinal diseases. In recent years, adaptive optics (AO)
      fundus imaging has proven its capability to image individual photoreceptor cells in the human
      retina. This technology is now reaching technical maturation. A prototypic AO system
      (manufactured by Imagine Eyes) is currently in operation in a clinical setting (Clinical
      Investigation Center 503) and has proven its reliability to monitor single photoreceptors
      over time. Yet, the clinical evaluation of AO imaging is still in its infancy, and biomarkers
      issued from AO imaging have not been validated. The goal of the iPhot project is thus to
      optimize the process of AO imaging (from the implementation of novel technical solution to
      image processing and data analysis) in order to obtain morphological, quantitative and
      longitudinal information concerning retinal microstructures in humans. For instance, we will
      aim at detecting early photoreceptor damage during retinal dystrophies.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>photoreceptor density</measure>
    <time_frame>01/12/2014</time_frame>
    <description>the variations of the density of photoreceptors over time will be evaluated</description>
  </primary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Retinal Dystrophies</condition>
  <condition>Age-related Macular Degeneration</condition>
  <condition>Arterial Hypertension</condition>
  <condition>Diabetes</condition>
  <condition>Traumatic Retinopathy</condition>
  <condition>Toxic Retinopathies</condition>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>subjects older than 10 years old, with no know ocular or general disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age-related macular degeneration</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>inherited retinal dystrophies</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>retinal trauma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>toxic retinopathies</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>arterial hypertensive patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>diabetic patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>inflammatory diseases</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        controls and patients with any kind of retinal alteration
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  over 10 years old

        Exclusion Criteria:

          -  ocular media opacities, unstable fixation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Paques, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quinze-Vingts Hospital, Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>michel paques, MD, PhD</last_name>
    <phone>+33 1 40 02 14 15</phone>
    <email>michel.paques@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Investigation Center 503</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>michel paques, MD, PhD</last_name>
      <phone>+33 1 40 02 14 15</phone>
      <email>michel.paques@gmail.com</email>
    </contact>
    <investigator>
      <last_name>michel Paques, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>photoreceptors</keyword>
  <keyword>retinal pigment epithelium</keyword>
  <keyword>adaptive optics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Retinal Dystrophies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

